Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)

NCT04626518 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

370

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Renal Cell

Interventions

BIOLOGICAL: Pembrolizumab
BIOLOGICAL: MK-4830
DRUG: Belzutifan
DRUG: Lenvatinib
BIOLOGICAL: Pembrolizumab/Quavonlimab
BIOLOGICAL: Favezelimab/Pembrolizumab

Sponsor

Merck Sharp & Dohme LLC